Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis

Platelets, long recognized for their role in hemostasis and thrombosis, have emerged as key players in a wide array of physiological and pathological processes through the release of platelet-derived extracellular vesicles (PEVs). These nanoscale vesicles, rich in bioactive molecules such as proteins, lipids, and nucleic acids, facilitate intercellular communication and influence processes ranging from angiogenesis and inflammation to immune modulation and tissue repair. PEVs, the most abundant extracellular vesicles in circulation, display procoagulant activity 50-100 times greater than activated platelets, underscoring their pivotal role in hemostasis and thrombosis. Recent research has unveiled their dual role in health and disease, highlighting their potential as diagnostic biomarkers and therapeutic vehicles. PEVs are implicated in cancer progression, autoimmune diseases, and infectious diseases, where they modulate tumor microenvironments, immune responses, and inflammatory pathways. Moreover, their ability to deliver therapeutic agents with high specificity and biocompatibility positions them as promising tools in regenerative medicine, drug delivery, and targeted therapies. This review comprehensively explores PEV biogenesis, cargo composition, and their multifaceted roles in hemostasis and thrombosis, as well as their broader implications in disease. It also explores the potential of PEVs as diagnostic markers and innovative therapeutic strategies, offering insights into their application in treating thrombotic disorders, cancer, and inflammatory diseases. Despite significant advancements, challenges remain in standardizing isolation protocols and translating preclinical findings into clinical applications. Unlocking the full potential of PEVs promises to revolutionize diagnostics and therapeutics, paving the way for novel approaches to managing complex diseases.

Перевод пока недоступен